Tumori (TUMORI )

Publisher: Istituto Nazionale per lo Studio e la Cura dei Tumori (Milano)


  • Impact factor
    Show impact factor history
    Impact factor
  • 5-year impact
  • Cited half-life
  • Immediacy index
  • Eigenfactor
  • Article influence
  • Website
    Tumori website
  • ISSN
  • OCLC
  • Material type
    Periodical, Internet resource
  • Document type
    Internet Resource, Computer File, Journal / Magazine / Newspaper

Publications in this journal

  • [Show abstract] [Hide abstract]
    ABSTRACT: Introduction. Breast cancer treatment currently represents one of the biggest chal- lenges in clinical oncology. The gold standard for axillary lymph node management is to perform sentinel node biopsy to avoid axillary dissection and its sequelae. The de- tection of radiocolloid flow outside the axillary nodes is a diagnostic and therapeutic challenge. Methods. A database search at the Department of Oncology of Palacky University, Olomouc, Czech Republic, identified 127 patients who underwent breast cancer re- section with a sentinel node procedure and had radiocolloid flow into the internal mammary nodes. Sentinel node lymphoscintigraphy was performed after intra- parenchymal injection. Clinical and pathological data were collected to identify pos- sible risk factors. Results. Ten clinical and pathological parameters including age, tumor histology, ax- illary lymph node status, estrogen receptor expression, progesterone receptor ex- pression, tumor grade, Ki-67 expression, Her-2 status, tumor size and tumor location were analyzed with regard to internal mammary node drainage. A cohort of 127 pa- tients with detected drainage into the internal mammary nodes was compared with 135 patients without such drainage. Six significant risk factors, including age <50 ye- ars (P <0.0313), tumor location in central and inner quadrants (P <0.012), larger tu- mor size (P <0.017), positive Her-2 status (P <0.025), progesterone receptor expres- sion (P <10-4) and axillary lymph node involvement (P <0.01) were found to predict ra- diocolloid flow into the internal mammary nodes. Conclusion. Six parameters (patient age, tumor location, hormone receptor status, tumor size, Her-2 status and axillary lymph node status) should be considered in the management of breast cancer patients and help in the selection of patients for lo- coregional procedures encompassing the internal mammary nodes.
    Tumori 07/2014; 100:254-258.
  • Tumori 06/2014;
  • Tumori 12/2013; 99.
  • [Show abstract] [Hide abstract]
    ABSTRACT: Abstract Aims and background. To summarize current knowledge on psychopharmacological and psychotherapeutic options for patients with breast cancer and comorbid depression, starting from the psychiatric viewpoint. Issues on diagnostic boundaries of depression and outcome measures are raised. Methods. We completed a literature review from the last 30 years (until March 2012) using PubMed by pairing the key words: 'breast cancer and depression treatment' (about 1431 works, including 207 reviews), 'breast cancer and antidepressants' (about 305 works, including 66 reviews), and in particular 'selective serotonin reuptake inhibitors and breast cancer' (38 works, including 10 reviews) and 'breast cancer and psychotherapy' (603 works, including 84 reviews). Papers in the English language were selected, including recent reviews. Results. There is little evidence for the superiority of any one specific intervention with pharmacological options or psychotherapy. The heterogeneity of assessment criteria, the small number of subjects collected in systematic studies, the difficulty in adopting standardized outcome measures, and the limited numbers of available drugs with a favorable side effect profile are the main limitations that emerge from the literature. No conclusive findings are available on mid-term/long-term treatment strategies, or when depression is part of a bipolar disorder. Conclusions. Further research is necessary to define the most appropriate approach to depression when it occurs in comorbidity with breast cancer. A more accurate definition of the clinical phenotypes of depression in the special population of patients with breast cancer is suggested as a key issue.
    Tumori 09/2013; 99(5):623-33.
  • [Show abstract] [Hide abstract]
    ABSTRACT: Aims and background. To investigate the efficacy and tolerability of biweekly scheduled triplet chemotherapy consisting of gemcitabine, cisplatin and vinorelbine for chemotherapy-naïve advanced non-small cell lung cancer. Methods and study design. Patients with stage IIIB/IV non-small cell lung cancer and performance status of 0-2 were eligible. Patients who had brain metastasis and of an older age were also enrolled in the study. The triplet combination chemotherapy consisted of gemcitabine, cisplatin and vinorelbine at the doses of 1000 mg/m2, 25 mg/m2 and 50 mg/m2, respectively, were administered on day 1 and 14, every 28 days, up to 6 cycles. Results. Thirty patients were enrolled in the study. Median age was 60 years (range, 42-74). Most of the patients (83%) had metastatic disease and 7 patients (23%) had brain metastasis. In assessing 24 patients for response evaluation, none had complete response. Partial responses were achieved in 18 (60%) patients. Four patients (13%) had stable disease and 2 (7%) progressed. Thirteen percent and 20% of the patients developed severe (grade 3-4) neutropenia and anemia, respectively. Febrile neutropenia, severe thrombocytopenia, hepatic and renal toxicity were not seen. Overall and progression-free survival were 8.15 and 7.15 months, respectively. Patients who had no brain metastasis ( P = 0.069), who had more than 3 courses of chemotherapy (P <0.001), and who had chemotherapy applied without dose reduction (P = 0.018) had better survivals. Conclusions. The biweekly schedule of the triplet chemotherapy combination including gemcitabine, cisplatin and vinorelbine was effective in advanced, mostly metastatic non-small cell lung cancer with acceptable and manageable side effects.
    Tumori 07/2013; 99(4):463-8.
  • [Show abstract] [Hide abstract]
    ABSTRACT: The case of a 72 year old woman with primary malignant melanoma of the esophagus, subjected twice to surgical operation with a 17-month interval and still alive 35 months after the onset symptoms is reported. In order to outline the biologic behaviour of this rare neoplasm, 44 similar bibliographic cases are analysed and comparisons made between melanoma and carcinoma of the esophagus as well as between melanomas of the esophagus and of the skin.
    Tumori 06/2013; 61(2):163-72.
  • Tumori 03/2013; 99(2):e55-60.
  • Tumori 01/2013; 99:e14-18.

Related Journals